Frontier Capital Management Co. LLC reduced its position in Illumina, Inc. (NASDAQ:ILMN) by 8.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 389,362 shares of the life sciences company’s stock after selling 34,514 shares during the period. Frontier Capital Management Co. LLC owned 0.27% of Illumina worth $85,072,000 at the end of the most recent quarter.
Several other large investors have also recently bought and sold shares of ILMN. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in shares of Illumina in the second quarter worth about $226,000. Riverhead Capital Management LLC lifted its position in shares of Illumina by 20.7% in the second quarter. Riverhead Capital Management LLC now owns 2,313 shares of the life sciences company’s stock worth $401,000 after buying an additional 397 shares in the last quarter. Laurion Capital Management LP purchased a new stake in shares of Illumina in the second quarter worth about $423,000. PNC Financial Services Group Inc. lifted its position in shares of Illumina by 6.9% in the second quarter. PNC Financial Services Group Inc. now owns 55,791 shares of the life sciences company’s stock worth $9,681,000 after buying an additional 3,577 shares in the last quarter. Finally, Rafferty Asset Management LLC lifted its position in shares of Illumina by 16.1% in the second quarter. Rafferty Asset Management LLC now owns 8,320 shares of the life sciences company’s stock worth $1,444,000 after buying an additional 1,153 shares in the last quarter. Institutional investors own 91.60% of the company’s stock.
Illumina, Inc. (NASDAQ ILMN) opened at $241.31 on Friday. The company has a market capitalization of $35,339.30, a P/E ratio of 45.19, a PEG ratio of 3.25 and a beta of 0.79. Illumina, Inc. has a 52 week low of $156.50 and a 52 week high of $248.97. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.73 and a current ratio of 4.22.
Illumina (NASDAQ:ILMN) last released its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 EPS for the quarter, beating analysts’ consensus estimates of $0.99 by $0.12. The firm had revenue of $714.00 million for the quarter, compared to analysts’ expectations of $692.77 million. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The company’s quarterly revenue was up 17.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.97 earnings per share. sell-side analysts forecast that Illumina, Inc. will post 3.76 EPS for the current year.
A number of equities research analysts recently commented on the company. BTIG Research reiterated a “hold” rating on shares of Illumina in a research report on Tuesday. Deutsche Bank set a $275.00 price objective on Illumina and gave the stock a “buy” rating in a research note on Tuesday. Wells Fargo & Co reissued a “positive” rating and set a $260.00 price objective (up from $250.00) on shares of Illumina in a research note on Tuesday, January 9th. Piper Jaffray Companies reissued a “buy” rating and set a $269.00 price objective on shares of Illumina in a research note on Tuesday, January 9th. Finally, William Blair cut Illumina from an “outperform” rating to a “market perform” rating in a research note on Friday, January 5th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $220.13.
In related news, EVP Marc Stapley sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 17th. The stock was sold at an average price of $242.33, for a total value of $484,660.00. Following the completion of the sale, the executive vice president now owns 29,815 shares in the company, valued at $7,225,068.95. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jay T. Flatley sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $243.72, for a total value of $3,655,800.00. Following the completion of the sale, the director now owns 449,201 shares of the company’s stock, valued at approximately $109,479,267.72. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 154,671 shares of company stock worth $33,626,228. Insiders own 0.89% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece of content was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of international copyright laws. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/19/illumina-inc-ilmn-shares-sold-by-frontier-capital-management-co-llc.html.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.